Journal article

Epigenetic reprogramming of plasmacytoid dendritic cells drives type I interferon-dependent differentiation of acute myeloid leukemias for therapeutic benefit

Jessica Salmon, Izabela Todorovski, Stephin Vervoort, Kym Stanley, Conor Kearney, Luciano Martelotto, Fernando Rossello, Tim Semple, Gisela Mir-Arnau, Magnus Zethoven, Michael Bots, Eva Vidacs, Kate McArthur, Elise Gressier, Nicky de Weerd, Jens Lichte, Madison Kelly, Leonie Cluse, Simon Hogg, Paul Hertzog Show all

Published : 2020


Pharmacological inhibition of epigenetic enzymes can have therapeutic benefit, particularly against hematological malignancies. While these agents can affect tumor cell growth and proliferation, recent studies have demonstrated that pharmacological de-regulation of epigenetic modifiers may additionally mediate anti-tumor immune responses. Here we discovered a novel mechanism of immune regulation through the inhibition of histone deacetylases (HDACs). In a genetically engineered model of t(8;21) AML, leukemia cell differentiation and therapeutic benefit mediated by the HDAC inhibitor panobinostat required activation of the type I interferon (IFN) signaling pathway. Plasmacytoid dendritic cell..

View full abstract